Wishbone/ITP, Inc.

Share this article:
Wishbone
Wishbone
245 Fifth Avenue, 12 Floor,
New York, NY 10016
Phone: 646-486-9701 · Fax:212-213-4235
Email: smichaelson@wishbone-itp.com · Web: www.wishbone-itp.com
Founded: 1998

Financial data:
Source20052004
Gross Income$11.1 mil$9.2 mil
Billings$81.6 mil$70.6 mil
US Employees5243

U.S. billings breakdown by media/source:
Medium20052004
Journals20.0%20.0%
Alternative media5.0%5.0%
Conventions/ exhibits10.0%10.0%
Direct marketing15.0%30.0%
Sales Materials45.0%35.0%
Other5.0%


Healthcare accounts: Abbott Laboratories: Depakote; Genzyme Corporation: Synvisc; Bristol-Myers Squibb Co.: Cefzil, Coumadin; Dey, LP: AccuNeb, EpiPen; MedPointe Pharmaceuticals: Astelin, Optivar; Reliant Pharmaceuticals, Inc.: Antara; Sigma-Tau Pharmaceuticals, Inc.: Matulane.

Accounts gained (6):

Accounts lost (0):

Services: The agency launched its new medical education division, Backbone. Diana Feed, Wishbone’s chief science officer, is the managing director and architect of this group. The agency’s strategy is to take its discovery process and apply the blueprint to a higher science, medical education arena. Backbone excels in developing advisory boards, editorial content, meetings, symposia, advocacy, publications planning, and Web-based activities.
Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro